Ibuprofen-mediated potential inhibition of biofilm development and quorum sensing in *Pseudomonas aeruginosa*

Lu Dai,^a Tian-qi Wu,^b Zhong-hui Wang,^a Ruoyu Yuan,^a Ye Ding,^a Wen-chen Zhang,^c Shao-peng Chu,^a Shao-qing Ju,^a Juan Yu^{a,d,#}

^a Department of Laboratory Medicine, Affiliated Hospital of Nantong University, 20 Xi Si Road, Nantong 226001, People's Republic of China

^b Glenelg Country School, 12793 Folly Quarter Rd, Ellicott City, Maryland, 21042, United States of America

^c Department of Clinical Laboratory, Wuxi Children's Hospital Affiliated to Nanjing Medical University, No. 299 at Qingyang Road, Wuxi 214023, People's Republic of China

^d Insitute of Public Health, Nantong University, 9 Se Yuan Road, Nantong 226001, People's Republic of China

Running Head

Ibuprofen inhibited *Pseudomonas aeruginosa*

#Corresponding author: Department of Laboratory Medicine, Affiliated Hospital of Nantong University, 20 Xi Si Road, Nantong 226001.

E-mail address: yujuanjs@163.com (Juan Yu)

Abstract

Pseudomonas aeruginosa is one of the leading causes of opportunistic and hospital-acquired infections worldwide. The infection with *P. aeruginosa* is frequently linked with clinical treatment difficulties given drug resistance and abuse of antibiotics. Ibuprofen, a widely used non-steroidal anti-inflammatory drug, has been previously reported to exert antimicrobial activity, although the specific mechanism of its action requires additional investigation. Given the regulation effects on quorum sensing (QS), we hypothesized that inhibition of *P. aeruginosa* with ibuprofen is linked with the QS systems. First, we assessed the action of ibuprofen in *P. aeruginosa* by measuring CFU. The antimicrobial activity of ibuprofen was evaluated

by crystal violet staining and acridine orange staining at various drug concentrations (0, 50, 75, and 100 µg/mL). Moreover, the effect of ibuprofen on different QS virulence factors, such as pyocyanin, elastase, protease, and rhamnolipids, was assessed revealing a concentration-dependent decrease ($P<0.05$). The effect of ibuprofen was confirmed by liquid chromatography/mass spectrometry analysis of 3-oxo-C₁₂-HSL and C₄-HSL production. In addition, qRT-PCR results identified significant suppression of Las and Rhl gene expression after 18 hours of treatment with ibuprofen ($P<0.05$), with the most significant suppression observed at the concentration of 75 µg/mL. Functional complementation with exogenous 3-oxo-C₁₂-HSL and C₄-HSL suggested that C₄-HSL can recover the production of virulence factors and biofilm formation in *P. aeruginosa*. Molecular docking of ibuprofen with QS-associated proteins revealed high binding affinity. In summary, the results suggest that ibuprofen is a candidate drug for the treatment of clinical infections with *P. aeruginosa*.

Keywords: *P. aeruginosa*, ibuprofen, antimicrobial activity, quorum sensing, N-acyl homoserine lactones

Introduction

Pseudomonas aeruginosa, the most common Gram-negative non-fermentative bacteria, is one of the leading causes of opportunistic and hospital-acquired infections worldwide(1). The infection can cause serious complications in patients with burns, cystic fibrosis, or in immunocompromised patients with respiratory infections, sepsis, osteomyelitis, endocarditis, and urinary tract infections (UTIs) (2). The infection with *P. aeruginosa* has been linked with difficulties in clinical treatment because of significant resistance of the bacterium to antibiotics (3), which is further aggravated by the worldwide abuse of antibiotics. Specifically, every year approximately 700,000 people die from antibiotic resistance worldwide, which can likely increase to 10 million by 2050 if no action is taken to reduce drug resistance or to develop new antibiotics. In 2017, the World Health Organization (WHO) published a list of drug-resistant bacteria threatening the lives of people which needs require for which

new antibiotics are critically needed. *P. aeruginosa* was listed second on the WHO list (4). Therefore, there is an urgent need to develop alternative strategies to treat *P. aeruginosa* infections.

Drug resistance in *P. aeruginosa* is mediated by complex mechanisms, wherein quorum sensing (QS) plays a significant role in virulence and pathogenicity. The system responsible for cell-to-cell communication in bacteria is mediated by QS, which relies on bacterial density to diffuse small signal molecules, N-acyl homoserine lactones (AHLs), that bind transcriptional activators to regulate gene expression. Studies report that QS controls expression of more than 300 genes involved in virulence factors synthesis, motility, phenotypic changes, biofilm formation, antibiotic resistance, and metabolic pathways that regulate stress response(5). *P. aeruginosa* has four QS systems: las, rhl, pqs, and iqs. Specifically, the lasI gene regulates the production of N-3-oxo-dodecanoyl-homoserine lactone (3-oxo-C₁₂-HSL), while the products of lasR, including lasI and rhlR-rhlI system, require sufficient levels of 3-oxo-C₁₂-HSL to activate virulence genes (6, 7). The rhl system produces N-butanoyl-L-homoserine lactone (C₄-HSL) to modulate virulence gene expression (8). The pqs system regulates the production of 2-heptyl-3-hydroxy-4(1H)-quinolone or simple quinolone and has been reported to control biofilm formation and the production of virulence factors (5, 9). Finally, the iqs system produces 2-(2-hydroxyphenyl)-thiazole-4-carbaldehyde but its exact role requires additional research.

Studies have shown that QS may increase the expression of virulence factors, such as pyocyanin, elastase, proteases, and rhamnolipids, to adapt to the environmental pressures (10). Pyocyanin, a part of blue redox-active pigment called phenazine, has been reported to modulate bis-(3',5')-cyclic dimeric guanosine (c-di-GMP) messenger and extracellular polymeric substance (EPS) (11). Moreover, pyocyanin regulates secretion of the extracellular DNA (eDNA) to mediate biofilm development (11). The activity of elastase is predominantly regulated by the extracellular virulence factor LasB (elastase). It is a zinc metalloprotease acting as a vital virulence factor to control the infection with *P. aeruginosa* (12). Proteases are involved in the pathogenesis of

acute lung injury caused by *P. aeruginosa* infection and are linked to the invasion and destruction of host tissue (13, 14). Rhamnolipids are biosurfactants that contribute to motility and biofilm development under stress conditions (15). Studies have shown that the level of virulence factors in QS-defective isolates is lower compared to wild-type isolates (16). Moreover, there is a relationship between the reduction in antibiofilm activity and increase in *rhIR* gene expression (17). Potential therapeutic strategies, attracting a lot of research attention, include targeting and inhibition of the QS system to treat *P. aeruginosa* infections.

Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), is one of the most popular non-prescription drugs given its high efficacy and safety. Early studies by Lee et al discovered that ibuprofen inhibited pulmonary vasoconstriction and bronchiolar constriction in pigs infected with *P. aeruginosa* (18). Moreover, in an acute *P. aeruginosa* pulmonary infection in mice, ibuprofen decreased the recruitment of granulocytes to airways and suppressed lung inflammation (19). Additionally, ibuprofen effectively inhibited the production of inflammatory factor-leukotriene B₄ (LTB₄) in turn reducing lung inflammation in a rat model of chronic pulmonary infection (20). Importantly, in a randomized controlled trial, two-thirds of female patients with uncomplicated UTIs who took ibuprofen recovered without additional antibiotic treatment (21). Until more studies are done to carefully identify patients needing antibiotics, ibuprofen cannot be recommended as a stand-alone therapy for UTI patients. However, it is an attractive treatment alternative to antibiotics that does not cause drug resistance.

Other studies have reported that ibuprofen inhibits the growth of *P. aeruginosa* in a dose-dependent manner(22). Moreover, ibuprofen can slow the progression of lung deterioration in patients with cystic fibrosis (23). Although multiple studies have suggested that ibuprofen exerts antimicrobial activity against Gram-negative bacteria, Gram-positive bacteria, fungi, and viruses (24-27), the underlying mechanism of antimicrobial activity of ibuprofen against *P. aeruginosa* remains unclear. In this study, we hypothesized that the inhibition of *P. aeruginosa* induced by ibuprofen is related to the QS systems.

Materials and methods

Microbial strain, growth conditions and chemicals

P. aeruginosa PAO1 (ATCC15692) strain was cultured in Luria-Bertani (LB) medium (Sangon Biotech, China). Ibuprofen was purchased from Sigma-Aldrich (Cat# 14883, St. Louis, MO, USA) and dissolved in dimethyl sulfoxide (DMSO) (Biosharp). Bacteria were streaked from -80°C skim milk stocks onto blood agar plates and incubated at 37°C . Single colonies were incubated in LB medium, shaking at 120 rpm overnight at 37°C .

Growth curve assessment

The cultures were diluted to 10^6 colony-forming units (CFU)/mL as the initial concentration. The growth curve of PAO1 was determined in the presence or absence of different ibuprofen concentrations (0, 50, 75, and $100\text{ }\mu\text{g/mL}$). The final DMSO concentration in all of the samples was 0.2% (v/v). All of the cultures at all of the time points (12 h, 18 h, and 24 h) were inoculated in the plates after dilution with sterile phosphate-buffered saline (PBS). The cell numbers of all of the groups were analyzed by the CFU plate count (22).

Biofilm formation assay

PAO1 was cultured in 96-well plates in the presence or absence of different ibuprofen concentrations (0, 50, 75, and $100\text{ }\mu\text{g/mL}$) for 24 h at 37°C . The cultures were removed and the plates were washed twice with PBS. The resulting biofilm was stained with 0.5% crystal violet for 15 min and solubilized in 95% alcohol. The absorbance was measured at 570 nm (28).

Microscopic assessment of adherence

PAO1 was incubated in 24-well plates in the presence or absence of ibuprofen with coverslips for 24 h at 37°C . The coverslips were washed with PBS and stained with $4\text{ }\mu\text{L}$ of 0.01% acridine orange (AO, Cat#A6014, Sigma) for 10 min in the dark. The samples were immediately observed under the fluorescent microscope (Olympus BX41, Japan) at $40\times$ lens magnification (28).

Evaluation of virulence factor production

We used four different assays to assess the levels and activity of (1) pyocyanin, (2) elastase, (3) protease, and (4) rhamnolipids. Specific details for each assay are outlined below.

1) Pyocyanin assay: PAO1 was cultured in the presence or absence of ibuprofen at 37°C. The supernatants were collected at different times (12h, 18h, 24h), extracted with 3 mL of chloroform, and subsequently mixed with 1 mL of 0.2 N HCl. The absorbance was measured at 520 nm.

2) Elastase activity: The elastase activity was determined by Elastin-Congo red (ECR, Sigma) test according to previously published methods (29, 30). Briefly, 600 µL of supernatant was mixed with 200 µL of ECR buffer (20 mg/mL in 0.1M Tris-HCl at pH 8 with 1 mM CaCl₂) and the mixture was incubated under shaking conditions (200 rpm) for 15 h at 37°C. Next, 100 µL of 0.12 M EDTA was used to stop the reaction. The undissolved ECR was removed by centrifugation at 5000 ×g at 10 min and the absorbance was measured at 495 nm.

3) Protease activity: The activity of protease was determined with 2% azocasein (Sigma) (30). Equal volumes of azocasein dissolved in PBS and supernatant were mixed and the cultures were incubated for 4 h at 4°C. Next, 500 µL of 10% trichloroacetic acid was added to stop the reaction and the cultures were spun at 10,000 ×g for 10 min. Finally, 500 µL of NaOH was mixed with the suspension and the absorbance was measured at 440 nm.

4) Rhamnolipid assay: Rhamnolipids were extracted from the supernatant by ethyl acetate using equal volumes (30). The samples were vortexed for 10 min and spun at 10,000 ×g for 5 min at 4°C. The upper layer was collected and the extraction process with ethyl acetate was repeated three times. The collected liquid was purified under N₂ gas evaporation system (Agela, USA). Finally, 900 µL of orcinol reagent (0.19% orcinol in 53% H₂SO₄) was added to the precipitate and the samples were incubated for 30 min at 80°C and the absorbance was measured at 420 nm.

High-performance liquid chromatography with triple quadrupole mass spectrometry analysis of 3-oxo-C₁₂-HSL and C₄-HSL

The extraction method of AHL is similar to that for rhamnolipids. Based on previous reports, we used 200 μ L of acetonitrile (ACN) with 0.1% formic acid to reconstitute AHLs (28, 30). Samples were injected through the C₁₈ reversed-phase column (3.5 μ m, 2.1 mm $\times$ 150 mm) (Waters, Milford, MA USA). The samples were analyzed using Shimadzu Nexera X2 HPLC system (Shimadzu Corporation, Japan) conjugated to AB Sciex 55000 triple quadrupole mass spectrometer (AB Sciex, Redwood City, CA USA). The flow rate of system was set to 0.3 mL/min with 0.1% (v/v) formic acid in water (as mobile phase A) and 0.1% (v/v) formic acid in ACN (as mobile phase B). The mobile phase gradient was increased to 60% B for the first 2 min after the column was equilibrated. Then the gradient was ramped to 100% B for up to 5 min and maintained for 7 min. Afterwards, the gradient was dropped to 50% B and the process was stopped at 12 min. The volume of the system was 5 μ L and the column temperature was maintained at 37°C. The conditions were as follows: capillary voltage, 4000V; temperature, 350°C; GS1, 40 psi; GS2: 40 psi; collision energy, 15 eV. Analysis was conducted with the following required parameters: m/z 298.2/197 for 3-oxo-C₁₂-HSL and m/z 172.0/102.1 for C₄HSL. The Analyst software (v. 1.2.1, AB Sciex) was used to create the calibration curve based on peak areas and analyze the data.

Gene expression analysis by quantitative real-time PCR (qRT-PCR)

Total RNA was extracted from the cultures using the TRIzol method (TRIzol reagent, Invitrogen, Carlsbad, CA USA) and was reverse-transcribed into cDNA using a kit according to the manufacturer's instructions (ThermoFisher Scientific, Waltham, MA, USA). The concentration and purity of RNA was determined using the UV spectrophotometer (Implen, Munchen, Germany). The process of qRT-PCR was performed by the LightCycler® 480 SYBR Green I Master (Roche, Germany) in a final reaction volume of 20 μ L. The expression of target genes was normalized to the expression of 16S used as a housekeeping gene. Primer sequences are listed in **Table 1**.

Binding analysis of ibuprofen and QS proteins

The binding interaction between the ibuprofen and proteins associated with *P*.

aeruginosa QS was performed by AutoDock (31). Crystal protein structures (LasR, LasI, LuxR, LasA, pqsA, and pqsR) were downloaded from PDB (<http://www.pdb.org>). Since there was no available structure for RhlR, we constructed it based on the homology model using Modeller 9.17 (32). Structure of ibuprofen was drawn in ChemBioDraw (v.14) software. The structures of ibuprofen and proteins were analyzed using AutoDockTools (v. 1.5.6) and docking was carried out by AutoDock Vina.

Functional complementation assays with 3-oxo-C₁₂-HSL and C₄-HSL

Exogenous 3-oxo-C₁₂-HSL and C₄-HSL at 2 μ M concentration were added to the PAO1 medium with ibuprofen in order to carry out functional complementation assays (33). The virulence factors were determined according to methods described above.

Statistical analysis

All of the experiments were conducted in triplicate and data are expressed as mean $\pm$ SD. The data were analyzed by one-way analysis of variance (ANOVA) using SPSS 20.0 software and the threshold for significance was set at a p -value < 0.05.

Results

Ibuprofen inhibits *P. aeruginosa* growth and biofilm formation

The bacterial burden showed a concentration-dependent reduction with increasing concentrations of ibuprofen (0, 50, 75, and 100 μ g/mL) at all examined time points (12 h, 18 h, and 24h). Exposure to 50 μ g/mL ibuprofen for 12 h resulted in a decrease in PAO1 count by nearly 0.7log₁₀ compared with the control (Figure 1.A). Importantly, the reduction in bacterial count increased to approximately 2log₁₀ when the concentration of ibuprofen was increased to 75 and 100 μ g/mL (Figure 1.A). All of the cultures treated with 100 μ g/mL ibuprofen had the lowest CFU counts at all of the examined time points. Since ibuprofen effectively inhibited bacterial growth, we hypothesized that ibuprofen exerts specific antibiofilm action against *P. aeruginosa*. Antibiofilm activity of ibuprofen was evaluated at several concentrations of ibuprofen by crystal violet staining. The results revealed that ibuprofen partly attenuated biofilm formation in *P. aeruginosa*, with the maximum reduction in biofilm formation (55%)

found at 100 $\mu\text{g/mL}$ (Figure 1.B). Next, the fluorescent microscopy was used to confirm the antibiofilm activity of ibuprofen. Specifically, *P. aeruginosa* was treated with ibuprofen and then AO was used for staining. Captured images indicated significant decrease in the attachment of biofilm cells at 100 $\mu\text{g/mL}$ ibuprofen and the changes reflected a concentration-dependent pattern (Figure 1.C). These data clearly suggest that ibuprofen effectively inhibits growth and biofilm development in a concentration-dependent manner.

Ibuprofen reduces QS signal synthesis in *P. aeruginosa*

To evaluate the action of ibuprofen on QS signaling molecules, we carefully examined the structures of 3-oxo- C_{12} -HSL and C_4 -HSL (Figure 2.A and B). The HPLC/MS analysis demonstrated that levels of 3-oxo- C_{12} -HSL were lower (17.08 ± 0.74 ng/mL) only at 100 $\mu\text{g/mL}$ ibuprofen at 12 h compared to the control group and there was no evidence of concentration-dependent changes at other examined time points (Figure 2.C). In contrast, we observed a significant ($P < 0.05$) time-dependent reduction in C_4 -HSL levels (Figure 2.D). PAO1 cultures treated with ibuprofen had significantly decreased levels of C_4 -HSL (up to 132.76 ng/mL) at all time points (12 h, 18 h, and 24 h). Overall, the inhibitory effects of ibuprofen on C_4 -HSL levels were concentration-dependent, with the unexceptional changes at 18 h and 24 h with the 75 $\mu\text{g/mL}$ concentration (Figure 2.C).

Ibuprofen attenuates the production of virulence factors in *P. aeruginosa*

Since our analysis identified that ibuprofen affected bacterial signaling, we next investigated the production of virulence factors regulated in *P. aeruginosa* PAO1 strain by QS. Upon treatment, 100 $\mu\text{g/mL}$ ibuprofen significantly ($P < 0.05$) reduced the release of pyocyanin (up to 24.5%) at all of the examined time points (Figure 3.A). Interestingly, the significant reduction in rhamnolipid production by ibuprofen was only seen at 18 h (26.2%) and 24 h (34.5%) (Figure 3.B). There were no significant effects of ibuprofen on rhamnolipid levels at 12 h after treatment (Figure 3.B). Similarly, the production of protease was effectively inhibited by ibuprofen at 12 h and 24 h and showed a concentration-dependent effect (Figure 3.C). In contrast, only moderate, but significant ($P < 0.05$), reduction (16.9%) in the total elastase production

(Figure 3.D) was observed at 100 µg/mL ibuprofen at 24 h. Overall, ibuprofen exerted a significant inhibitory effect on the virulence factor production at 24 h.

The expression of QS genes decreases after ibuprofen treatment

To examine whether ibuprofen affected changes in *P. aeruginosa* on a molecular level, we analyzed gene expression levels associated with QS system by qRT-PCR (Figure 4). We noted significant ($P<0.05$) reduction in the expression of *lasI*, *lasR*, *rhlI*, *rhlR*, *pqsA*, and *pqsR* at 18 h. However, the effect did not follow a concentration-dependent pattern, like in the case of virulence factor assessment. Among all of the examined concentrations, 75 µg/mL exerted the most pronounced effects in suppressing QS system gene expression. The relative expression of *lasI* and *lasR* was decreased 1.5- and 3.5-fold, respectively (Figure 4.A and B), while the expression of *pqsA* and *pqsR* was reduced by approximately 1.5~2.0-fold (Figure 4.C and D). Most interesting, the levels of *rhlI* were reduced 4.7-fold and the levels of *rhlR* was suppressed 8.3-fold (Figure 4.E and F). These data suggest that ibuprofen mainly acted on the Rhl and Las system.

Given the inhibition of QS signaling molecules, we examined whether exogenous addition of 3-oxo- C_{12} -HSL and C_4 -HSL could functionally complement the activity of ibuprofen. Specifically, we observed a significant increase ($P<0.05$) in biofilm formation (Figure 5.A), pyocyanin production (Figure 5.B), elastase activity (Figure 5.C), protease activity (Figure 5.D), and rhamnolipid production (Figure 5.E) upon addition of exogenous C_4 -HSL. Importantly, we did not observe any statistically significant changes in the level of virulence factors upon treatment with exogenous 3-oxo- C_{12} -HSL (Figure 5).

Assessment of molecular docking of ibuprofen with QS-related proteins in *P. aeruginosa*

To further analyze the role of ibuprofen, molecular docking study was performed to better understand the effect of ibuprofen on attenuating QS-related proteins (*LasA*, *LasI*, *RhlR*, *LuxR*, *LasR*, *PqsA*, and *PqsR*). Crystal structures of the QS-related proteins were found online: *LasR* (PDB ID: 2UV0), *LasI* (PDB ID: IRO5), *LuxR* (PDB ID: 3JPU), *LasA* (PDB ID: 3IT7), *PqsA* (PDB ID: 5OE3), and *PqsR* (PDB

ID:5OE3). Although the crystal structure of RhlR was not available, we obtained it by
homology modeling. The native receptors and binding affinity of ibuprofen with
QS-related proteins is summarized in **Table 2**. Specifically, we observed that
ibuprofen was docked with LasA at two different binding pockets occupied by two
different ligands: tartaric acid (TLA) and glycerol (GOL). The binding energy
computed using AutoDock between ibuprofen and LasA was -6.7 kcal/mol with the
GOL ligand (**Table 2**). Moreover, ibuprofen formed three hydrogen bonds with Ser50
of LasA at a distance of 3.0, 3.2 and 3.4 Å (Figure 6.A). In addition, ibuprofen formed
a hydrogen bond with Arg12 of LasA at a distance of 3.4 Å (Figure 6.A). The results
of AutoDock analysis suggested that ibuprofen only formed a hydrogen bond with
Ile107 of LasI (Figure 6.B). The binding energy between ibuprofen and LasI was -7.4
kcal/mol (**Table 2**). We constructed a virtual homology model of RhlR since the
crystal structure was not available. Here, ibuprofen formed two hydrogen bonds with
Asp80 of RhlR at a distance of 1.5 and 3.3 Å (Figure 6.C). The docking score
between ibuprofen and RhlR was -7.2 kcal/mol (**Table 2**). Moreover, ibuprofen
formed two hydrogen bonds with Thr75 and Asp73 in LuxR at a distance of 3.2 and
1.9 Å, respectively (Figure 6.D). The result showed that binding energy between
ibuprofen and LuxR was -7.9 kcal/mol (**Table 2**). The docking studies showed that
ibuprofen binds into the active site of LasR with Asp73, Thr75, Thr115, and Ser129
residues by hydrogen bond interactions (Figure 6.E). The binding energy between
ibuprofen and LasR was -7.7 kcal/mol (**Table 2**). PqsA was shown to interact with
four different ligands, and
5'-O-[(S)-[(2-aminobenzoyl)oxy](hydroxy)phosphoryl]adenosine (3UK) with high
binding scores (-6.8 kcal/mol) (**Table 2**). Ibuprofen formed hydrogen bonds with
Asp299, Ser280, Gly279, and Gly300 residues at a distance of 1.9, 3.2, 2.5, and 3.4 Å,
respectively (Figure 6.F). Furthermore, ibuprofen was found to interact with the
Ser196 and Gln194 of PqsR (Figure 6.G) and showed binding energy of -6.8 kcal/mol
(**Table 2**). After docking of ibuprofen into the original ligand binding pockets of these
proteins, we found that ibuprofen was binding with LuxR (-7.9 kcal/mol), LasR (-7.7
kcal/mol), LasI (-7.4 kcal/mol), and RhlR (-7.2 kcal/mol) with high binding scores

(**Table 2**). Thus, the molecular docking data further demonstrate that ibuprofen may inhibit the LuxR, Las, and Rhl systems in *P. aeruginosa*.

Discussion

Inhibitors of QS which act to directly prevent biofilm formation and limit virulence factor release are being considered as a novel strategy for treating *P. aeruginosa* infections (34-36). Although many studies examined the action of ibuprofen in bacterial infections, the antibacterial mechanism of action of ibuprofen requires further exploration. The first mention of the antifungal and antimicrobial activity of ibuprofen was reported by Hersh and colleagues in 1991. Many reports have demonstrated that ibuprofen exerts antibacterial effects in high concentrations that exceed levels seen in normal human blood (24, 37, 38). Previous report indicated that ibuprofen was able to prevent AHL inhibition of the responses to nucleotides in cystic fibrosis airway epithelium (39). Moreover, ibuprofen has been reported as an alternative drug for the treatment of local infections (e.g., UTIs) and showed a promising therapeutic potential when combined with clinical antibiotics (21, 24, 40-42).

In this study, we confirmed that ibuprofen has antimicrobial activity and specifically reduces the QS signaling molecules. Based on the clinical trial data, the efficacy and safety of high-dose ibuprofen (50–100 µg/mL plasma concentration) was shown in cystic fibrosis patients (22). Based on these data, we designed a concentration gradient of ibuprofen that was tested. We discovered that ibuprofen can affect the growth of *P. aeruginosa* but it may not have a complete bactericidal effect (Figure 1.A). The OA staining assay demonstrated that the attachment activity of *P. aeruginosa* was inhibited by ibuprofen in a concentration-dependent manner (Figure 1.C). Biofilm is defined as the community of bacteria attached to both biological and abiotic surfaces, and the presence of biofilm further exacerbates the crisis of antibiotic resistance worldwide (43). Crystal violet staining confirmed that ibuprofen exerted a significant effect on the reduction of biofilm formation by *P. aeruginosa* (Figure 1.B), with the 100 µg/mL concentration having the greatest effect on biofilm inhibition.

We next determined that the synthesis of C₄-HSL was inhibited by ibuprofen in a concentration- and time-dependent manner (Figure 2.C). However, ibuprofen did not reduce 3-oxo-C₁₂-HSL secretion, suggesting that ibuprofen exerts antimicrobial effects through the reduction of C₄-HSL levels instead of the direct cell death effects (Figure 1 and 2).

Many studies have been conducted to identify that QS molecules act as regulators mediating the production of virulence factors (36, 44). Studies in different animal models demonstrate that QS plays a critical role in the pathogenicity of *P. aeruginosa* infections (10, 17, 45, 46). In this study, we found that the virulence factors, including pyocyanin, elastase, protease, and rhamnolipids, were significantly reduced upon treatment with ibuprofen at the 24 h time point in a concentration-dependent manner (Figure 3). We concluded that treatment with ibuprofen specifically and effectively targets QS molecules and virulence factors in *P. aeruginosa* and can therefore be a promising clinical therapy.

Las and Rhl are involved in the LuxR-type QS system of *P. aeruginosa*. Gene expression analysis revealed significant decreases in genes encoding QS proteins (lasI, lasR, rhlI, rhlR, pasA, and pqsR) following ibuprofen treatment within 18 h (Figure 4). Despite these findings, the inhibition by ibuprofen did not show concentration-dependent changes and future studies are needed to address this finding in detail. Work by Somaia. et al suggested that aspirin, another NSAID, reduces lasR gene expression by competing with 3-oxo-C₁₂-HSL (47). In our findings, ibuprofen significantly repressed lasR and rhlR gene expression by 88.3% and 88%, respectively. The antimicrobial activity of ibuprofen against *P. aeruginosa* is dependent on lasR and rhlR. The reduction in pqsA and pqsR gene expression levels by ibuprofen was almost 75%. In our study, the decreased level of virulence factors was consistent with the reduction in QS systems related to the effects on Las and Rhl gene expression (Figure 3 and 4).

To further investigate the antimicrobial activity of ibuprofen, we examined the molecular interaction of QS-associated LasR, LasI, LuxR, LasA, RhlR, PqsA, and PqsR proteins with ibuprofen. Our docking studies of ibuprofen with proteins

suggested that ibuprofen specifically binds to ligand binding pockets in four of the QS proteins LuxR, LasR, LasI, and RhlR with a relatively high binding affinity (Figure 6 and **Table 2**). Amino acids presenting in the binding sites of these four proteins play crucial roles in the dimerization and activation of the receptors. Based on our results, we propose that the binding of ibuprofen to the amino acids might be directly responsible for the inactivation of the QS proteins. We believe that this occurs either by preventing protein dimerization or there are direct effects on the DNA resulting in suppression of gene expression downstream in the QS system. Overall, the data suggest that the proteins related to QS may be a promising target for antibacterial and antibiofilm action of ibuprofen.

Moreover, we also examined whether exogenous addition of 3-oxo-C₁₂-HSL and C₄-HSL can functionally complement the activity of ibuprofen. We observed that C₄-HSL was capable of reversing the antimicrobial action of ibuprofen on biofilm formation and virulence factors, whereas 3-oxo-C₁₂-HSL had no effect (Figure 5). These data recapitulated the LC/MS results. Although 3-oxo-C₁₂-HSL-LasR can directly activate transcription of target genes and stimulate the production of C₄-HSL and RhlR, the action of ibuprofen was not inhibited by 3-oxo-C₁₂-HSL. These results warrant additional investigation to further explore the specific antimicrobial role of ibuprofen.

In summary, we demonstrated the molecular mechanism of antibacterial activity of ibuprofen against *P. aeruginosa*. In our study, ibuprofen prevented the *P. aeruginosa* by directly reducing bacterial burden and suppressing the LuxR QS system. Considering the gene expression results and effect on virulence factors, treatment with ibuprofen may be a promising therapy when dealing with *P. aeruginosa* infections. Additionally, because other studies suggest that ibuprofen is effective in treating UTIs and cystic fibrosis, we propose ibuprofen as a candidate drug to be used in the management of clinical infections with *P. aeruginosa*.

Acknowledgements

This work was supported by the Science and Technology Project of Nantong city

(2018).

Conflict of interest

The authors declare they have no financial conflicts of interest.

References

1. Pang Z, Raudonis R, Glick BR, Lin TJ, Cheng Z. 2019. Antibiotic resistance in *Pseudomonas aeruginosa*: mechanisms and alternative therapeutic strategies. *Biotechnol Adv* 37:177-192.
2. Moradali MF, Ghods S, Rehm BH. 2017. *Pseudomonas aeruginosa* Lifestyle: A Paradigm for Adaptation, Survival, and Persistence. *Front Cell Infect Microbiol* 7:39.
3. Chevalier S, Bouffartigues E, Bodilis J, Maillot O, Lesouhaitier O, Feuilloley MGJ, Orange N, Dufour A, Cornelis P. 2017. Structure, function and regulation of *Pseudomonas aeruginosa* porins. *FEMS Microbiol Rev* 41:698-722.
4. Willyard C. 2017. The drug-resistant bacteria that pose the greatest health threats. *Nature* 543:15.
5. Azam MW, Khan AU. 2019. Updates on the pathogenicity status of *Pseudomonas aeruginosa*. *Drug Discov Today* 24:350-359.
6. Davies DG, Parsek MR, Pearson JP, Iglewski BH, Costerton JW, Greenberg EP. 1998. The involvement of cell-to-cell signals in the development of a bacterial biofilm. *Science* 280:295-8.
7. Jakobsen TH, Bjarnsholt T, Jensen PO, Givskov M, Hoiby N. 2013. Targeting quorum sensing in *Pseudomonas aeruginosa* biofilms: current and emerging inhibitors. *Future Microbiol* 8:901-21.
8. Jimenez PN, Koch G, Thompson JA, Xavier KB, Cool RH, Quax WJ. 2012. The multiple signaling systems regulating virulence in *Pseudomonas aeruginosa*. *Microbiol Mol Biol Rev* 76:46-65.
9. Lee J, Zhang L. 2015. The hierarchy quorum sensing network in *Pseudomonas*

aeruginosa. Protein Cell 6:26-41.

10. Karatuna O, Yagci A. 2010. Analysis of quorum sensing-dependent virulence factor production and its relationship with antimicrobial susceptibility in *Pseudomonas aeruginosa* respiratory isolates. Clin Microbiol Infect 16:1770-5.

11. Meirelles LA, Newman DK. 2018. Both toxic and beneficial effects of pyocyanin contribute to the lifecycle of *Pseudomonas aeruginosa*. Mol Microbiol 110:995-1010.

12. Szamosvari D, Reichle VF, Jureschi M, Bottcher T. 2016. Synthetic quinolone signal analogues inhibiting the virulence factor elastase of *Pseudomonas aeruginosa*. Chem Commun (Camb) 52:13440-13443.

13. Kipnis E, Sawa T, Wiener-Kronish J. 2006. Targeting mechanisms of *Pseudomonas aeruginosa* pathogenesis. Med Mal Infect 36:78-91.

14. Lindsay S, Oates A, Bourdillon K. 2017. The detrimental impact of extracellular bacterial proteases on wound healing. Int Wound J 14:1237-1247.

15. Reis RS, Pereira AG, Neves BC, Freire DM. 2011. Gene regulation of rhamnolipid production in *Pseudomonas aeruginosa*--a review. Bioresour Technol 102:6377-84.

16. Garcia-Contreras R. 2016. Is Quorum Sensing Interference a Viable Alternative to Treat *Pseudomonas aeruginosa* Infections? Front Microbiol 7:1454.

17. Gholamrezazadeh M, Shakibaie MR, Monirzadeh F, Masoumi S, Hashemizadeh Z. 2018. Effect of nano-silver, nano-copper, deconex and benzalkonium chloride on biofilm formation and expression of transcription regulatory quorum sensing gene (rhIR) in drug-resistance *Pseudomonas aeruginosa* burn isolates. Burns 44:700-708.

18. Lee CC, Sugerman HJ, Tatum JL, Wright TP, Hirsh PD, Hirsch JJ. 1986. Effects of ibuprofen on a pig *Pseudomonas* ARDS model. J Surg Res 40:438-44.

19. Sordelli DO, Cerquetti MC, el-Tawil G, Ramwell PW, Hooke AM, Bellanti JA. 1985. Ibuprofen modifies the inflammatory response of the murine lung to

- 483 *Pseudomonas aeruginosa*. *Eur J Respir Dis* 67:118-27.
- 484 20. Konstan MW, Vargo KM, Davis PB. 1990. Ibuprofen attenuates the
485 inflammatory response to *Pseudomonas aeruginosa* in a rat model of chronic
486 pulmonary infection. Implications for antiinflammatory therapy in cystic
487 fibrosis. *Am Rev Respir Dis* 141:186-92.
- 488 21. Gagyor I, Bleidorn J, Kochen MM, Schmiemann G, Wegscheider K,
489 Hummers-Pradier E. 2015. Ibuprofen versus fosfomycin for uncomplicated
490 urinary tract infection in women: randomised controlled trial. *Bmj* 351:h6544.
- 491 22. Shah PN, Marshall-Batty KR, Smolen JA, Tagaev JA, Chen Q, Rodesney CA,
492 Le HH, Gordon VD, Greenberg DE, Cannon CL. 2018. Antimicrobial Activity
493 of Ibuprofen against Cystic Fibrosis-Associated Gram-Negative Pathogens.
494 *Antimicrob Agents Chemother* 62:1-22.
- 495 23. Lands LC, Stanojevic S. 2016. Oral non-steroidal anti-inflammatory drug
496 therapy for lung disease in cystic fibrosis. *Cochrane Database Syst Rev*
497 4:Cd001505.
- 498 24. Obad J, Suskovic J, Kos B. 2015. Antimicrobial activity of ibuprofen: new
499 perspectives on an "Old" non-antibiotic drug. *Eur J Pharm Sci* 71:93-8.
- 500 25. Ogundeji AO, Pohl CH, Sebolai OM. 2016. Repurposing of Aspirin and
501 Ibuprofen as Candidate Anti-Cryptococcus Drugs. *Antimicrob Agents*
502 *Chemother* 60:4799-808.
- 503 26. Pan T, Peng Z, Tan L, Zou F, Zhou N, Liu B, Liang L, Chen C, Liu J, Wu L,
504 Liu G, Peng Z, Liu W, Ma X, Zhang J, Zhu X, Liu T, Li M, Huang X, Tao L,
505 Zhang Y, Zhang H. 2018. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
506 Potently Inhibit the Replication of Zika Viruses by Inducing the Degradation
507 of AXL. *J Virol* doi:10.1128/jvi.01018-18.
- 508 27. Laudy AE, Mrowka A, Krajewska J, Tyski S. 2016. The Influence of Efflux
509 Pump Inhibitors on the Activity of Non-Antibiotic NSAIDS against
510 Gram-Negative Rods. *PLoS One* 11:e0147131.
- 511 28. Chatterjee M, D'Morris S, Paul V, Warriar S, Vasudevan AK, Vanuopadath M,
512 Nair SS, Paul-Prasanth B, Mohan CG, Biswas R. 2017. Mechanistic

- 513 understanding of Phenyllactic acid mediated inhibition of quorum sensing and
514 biofilm development in *Pseudomonas aeruginosa*. *Appl Microbiol Biotechnol*
515 101:8223-8236.
- 516 29. Das MC, Sandhu P, Gupta P, Rudrapaul P, De UC, Tribedi P, Akhter Y,
517 Bhattacharjee S. 2016. Attenuation of *Pseudomonas aeruginosa* biofilm
518 formation by Vitexin: A combinatorial study with azithromycin and
519 gentamicin. *Sci Rep* 6:23347.
- 520 30. Jack AA, Khan S, Powell LC, Pritchard MF, Beck K, Sadh H, Sutton L,
521 Cavaliere A, Florance H, Rye PD, Thomas DW, Hill KE. 2018. Alginate
522 Oligosaccharide-Induced Modification of the lasI-lasR and rhlI-rhlR
523 Quorum-Sensing Systems in *Pseudomonas aeruginosa*. *Antimicrob Agents*
524 *Chemother* 62:1-14.
- 525 31. Trott O, Olson AJ. 2010. AutoDock Vina: improving the speed and accuracy
526 of docking with a new scoring function, efficient optimization, and
527 multithreading. *J Comput Chem* 31:455-61.
- 528 32. Fiser A, Sali A. 2003. Modeller: generation and refinement of homology-based
529 protein structure models. *Methods Enzymol* 374:461-91.
- 530 33. Babic F, Venturi V, Maravic-Vlahovicek G. 2010. Tobramycin at subinhibitory
531 concentration inhibits the RhlI/R quorum sensing system in a *Pseudomonas*
532 *aeruginosa* environmental isolate. *BMC Infect Dis* 10:148.
- 533 34. Janssens JC, De Keersmaecker SC, De Vos DE, Vanderleyden J. 2008. Small
534 molecules for interference with cell-cell-communication systems in
535 Gram-negative bacteria. *Curr Med Chem* 15:2144-56.
- 536 35. Hardman AM, Stewart GS, Williams P. 1998. Quorum sensing and the
537 cell-cell communication dependent regulation of gene expression in
538 pathogenic and non-pathogenic bacteria. *Antonie Van Leeuwenhoek*
539 74:199-210.
- 540 36. Le Berre R, Faure K, Nguyen S, Pierre M, Ader F, Guery B. 2006. [Quorum
541 sensing: a new clinical target for *Pseudomonas aeruginosa*?]. *Med Mal Infect*
542 36:349-57.

- 543 37. Elvers KT, Wright SJ. 1995. Antibacterial activity of the anti-inflammatory
544 compound ibuprofen. *Lett Appl Microbiol* 20:82-4.
- 545 38. Pina-Vaz C, Sansonetty F, Rodrigues AG, Martinez-De-Oliveira J, Fonseca AF,
546 Mardh PA. 2000. Antifungal activity of ibuprofen alone and in combination
547 with fluconazole against *Candida* species. *J Med Microbiol* 49:831-40.
- 548 39. Saleh A, Figarella C, Kammouni W, Marchand-Pinatel S, Lazdunski A, Tubul
549 A, Brun P, Merten MD. 1999. *Pseudomonas aeruginosa* quorum-sensing signal
550 molecule N-(3-oxododecanoyl)-L-homoserine lactone inhibits expression of
551 P2Y receptors in cystic fibrosis tracheal gland cells. *Infect Immun* 67:5076-82.
- 552 40. Little P. 2017. Antibiotics or NSAIDs for uncomplicated urinary tract infection?
553 *Bmj* 359:j5037.
- 554 41. Vik I, Bollestad M, Grude N, Baerheim A, Damsgaard E, Neumark T, Bjerrum
555 L, Cordoba G, Olsen IC. 2018. Ibuprofen versus pivmecillinam for
556 uncomplicated urinary tract infection in women-A double-blind, randomized
557 non-inferiority trial. *PLoS Med* 15:e1002569.
- 558 42. Pina-Vaz C, Rodrigues AG, Costa-de-Oliveira S, Ricardo E, Mardh PA. 2005.
559 Potent synergic effect between ibuprofen and azoles on *Candida* resulting
560 from blockade of efflux pumps as determined by FUN-1 staining and flow
561 cytometry. *J Antimicrob Chemother* 56:678-85.
- 562 43. Mathur H, Field D. 2018. Fighting biofilms with lantibiotics and other groups
563 of bacteriocins. *NPJ Biofilms Microbiomes* 4:9.
- 564 44. Alayande AB, Aung MM, Kim IS. 2018. Correlation Between Quorum
565 Sensing Signal Molecules and *Pseudomonas aeruginosa*'s Biofilm
566 Development and Virulency. *Curr Microbiol* 75:787-793.
- 567 45. Cosson P, Zulianello L, Join-Lambert O, Faurisson F, Gebbie L, Benghezal M,
568 Van Delden C, Curty LK, Kohler T. 2002. *Pseudomonas aeruginosa* virulence
569 analyzed in a *Dictyostelium discoideum* host system. *J Bacteriol* 184:3027-33.
- 570 46. Rahme LG, Stevens EJ, Wolfort SF, Shao J, Tompkins RG, Ausubel FM. 1995.
571 Common virulence factors for bacterial pathogenicity in plants and animals.
572 *Science* 268:1899-902.

47. El-Mowafy SA, Abd El Galil KH, El-Messery SM, Shaaban MI. 2014. Aspirin is an efficient inhibitor of quorum sensing, virulence and toxins in *Pseudomonas aeruginosa*. *Microb Pathog* 74:25-32.

Figure legends:

Figure 1. Concentration-dependent effects of ibuprofen on inhibiting the growth and biofilm formation in *P. aeruginosa*. (A) Growth conditions. (B) Adherence ability. a. 0 µg/mL ibuprofen; b. 50 µg/mL ibuprofen; c. 75 µg/mL ibuprofen; d. 100 µg/mL ibuprofen (original magnification, ×40). (C) Biofilm formation. *P. aeruginosa* PAO1 treated with different concentrations of ibuprofen (0, 50, 75, and 100 µg/mL). Data are represented as mean of four independent experiments and presented as mean ± SD. * indicates $P<0.05$, ** indicates $P<0.01$.

Figure 2. Effect of ibuprofen on AHL concentrations as determined by LC/MS. (A) Structure of 3-oxo-C₁₂-HSL. (B) Structure of C₄-HSL. (C) 3-oxo-C₁₂-HSL production. (D) C₄-HSL production. (E) LC/MS peaks of 3-oxo-C₁₂-HSL and C₄-HSL. AHL concentrations of *P. aeruginosa* PAO1 treated with different concentrations of ibuprofen (0, 50, 75, and 100 µg/mL) evaluated at three time points (12 h, 18 h, and 24 h). Data are represented as mean of three independent experiments and presented as mean ± SD. * indicates $P<0.05$, ** indicates $P<0.01$.

Figure 3. Extracellular virulence factor levels in cell-free culture supernatants treated with ibuprofen. (A) Pyocyanin. (B) Rhamnolipids. (C) Protease. (D) Elastase. *P. aeruginosa* PAO1 treated with different concentrations of ibuprofen (0, 50, 75, and 100 µg/mL) and extracellular virulence factors in the supernatants determined at three time points (12 h, 18 h, and 24 h). Data are represented as mean of three independent experiments and presented as mean ± SD. * indicates $P<0.05$, ** indicates $P<0.01$.

Figure 4. The changes in gene expression related to the QS system in *P. aeruginosa* treated with ibuprofen. (A) *lasI*. (B) *lasR*. (C) *pqsA*. (D) *pqsR*. (E) *rhII*.

(F) *rhlR*. *P. aeruginosa* PAO1 was treated with different concentrations of ibuprofen (0, 50, 75, 100 µg/mL) and the gene expression changes were evaluated at three time points (12 h, 18 h, and 24 h). Data are represented as mean of three independent experiments and presented as mean ± SD. * indicates $P < 0.05$, ** indicates $P < 0.01$.

Figure 5. Functional complementation of ibuprofen-treated *P. aeruginosa* with exogenous 3-oxo-C₁₂-HSL and C₄-HSL. (A) Biofilm formation. (B) Pyocyanin. (C) Elastase. (D) Protease. (E) Rhamnolipids. The determination of virulence factor production and biofilm formation in *P. aeruginosa* PAO1 treated with ibuprofen (100 µg/mL) in the presence of 3-oxo-C₁₂-HSL and C₄-HSL. Data are represented as mean of three independent experiments and presented as mean ± SD. * indicates $P < 0.05$, ** indicates $P < 0.01$.

Figure 6. Ibuprofen docked in different binding pockets of QS proteins in *P. aeruginosa*. (A) Cartoon structure of LasA with ibuprofen. (B) Cartoon structure of LasI with ibuprofen. (C) Cartoon structure of RhlR with ibuprofen. (D) Cartoon structure of LuxR with ibuprofen. (E) Cartoon structure of LasR with ibuprofen. (F) Cartoon structure of PqsA with ibuprofen. (G) Cartoon structure of PqsR with ibuprofen. Proteins are represented in cartoons and ligands are represented in stick models.

Table 1. List of primers used in qRT-PCR.

Target name	Type	Primer sequence	References
<i>lasI</i>	Fw	5'-CGCACATCTGGGAACTCA-3'	(46)
	Rev	5'- CGGCACGGATCATCATCT-3'	
<i>lasR</i>	Fw	5'- CTGTGGATGCTCAAGGACTAC-3'	
	Rev	5'- AACTGGTCTTGCCGATGG-3'	
<i>rhlI</i>	Fw	5'- GTAGCGGGTTTGCGGATG-3'	
	Rev	5'- CGGCATCAGGTCTTCATCG-3'	
<i>rhlR</i>	Fw	5'- GCCAGCGTCTTGTTCCGG-3'	
	Rev	5'- CGGTCTGCCTGAGCCATC-3'	
<i>pqsA</i>	Fw	5'- GACCGGCTGTATTCGATTG-3'	
	Rev	5'- GCTGAACCAGGGAAAGAAC-3'	
<i>pqsR</i>	Fw	5'- CTGATCTGCCGGTAATTGG-3'	(47)
	Rev	5'- ATCGACGAGGAACTGAAGA-3'	
16S	Fw	5'-GAGGAAGGTGGGGATGACGT-3'	(47)
	Rev	5'-AGGCCCCGGGAACGTATTCAC-3'	

Table 2. Binding affinity of QS regulator proteins from *P. aeruginosa* with ibuprofen.

Receptor protein	PDB ID	Native ligand	Probable inhibitor	Hydrogen bonds	Binding energy(kcal/mol)
LasA	3IT7	GOL	Ibuprofen	Ser50, Arg12	-6.7
LasI	1RO5	perrhenate	Ibuprofen	Ile107	-7.4
RhlR	4Y15	-	Ibuprofen	Asp80	-7.2
LuxR	3JPU	TY4	Ibuprofen	Thr75, Asp73	-7.9
LasR	2UV0	OHN	Ibuprofen	Asp73, Thr75, Thr115, Ser129	-7.7
PqsA	5OE3	3UK	Ibuprofen	Asp299, Ser280, Gly279, Gly300	-6.8
PqsR	4JVD	NNQ	Ibuprofen	Ser196, Gln194	-6.7

AutoDock provides a binding score revealing the binding affinity measured in kcal/mol. Negative scores indicate high binding affinity.

A

B

(i)

(ii)

(iii)

(iiii)

C

A

B

E

C

D

A

Pyocyanin

B

Rhamnolipid

C

Protease

D

Elastase

A

B

C

D

E

F

A

B

C

D

E

A. LasA

B. LasI

C. RhIR

D. LuxR

E. LasR

F. PqsA

G. PqsR